158 related articles for article (PubMed ID: 31729149)
21. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
22. Sample size computation for two-sample noninferiority log-rank test.
Jung SH; Kang SJ; McCall LM; Blumenstein B
J Biopharm Stat; 2005; 15(6):969-79. PubMed ID: 16279355
[TBL] [Abstract][Full Text] [Related]
23. Analysis and design of randomised clinical trials involving competing risks endpoints.
Tai BC; Wee J; Machin D
Trials; 2011 May; 12():127. PubMed ID: 21595883
[TBL] [Abstract][Full Text] [Related]
24. Test Statistics and Confidence Intervals to Establish Noninferiority between Treatments with Ordinal Categorical Data.
Zhang F; Miyaoka E; Huang F; Tanaka Y
J Biopharm Stat; 2015; 25(5):921-38. PubMed ID: 24919157
[TBL] [Abstract][Full Text] [Related]
25. The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards.
Dong G; Huang B; Chang YW; Seifu Y; Song J; Hoaglin DC
Pharm Stat; 2020 May; 19(3):168-177. PubMed ID: 31671481
[TBL] [Abstract][Full Text] [Related]
26. A weighted log-rank test and associated effect estimator for cancer trials with delayed treatment effect.
Yu C; Huang X; Nian H; He P
Pharm Stat; 2021 May; 20(3):528-550. PubMed ID: 33427400
[TBL] [Abstract][Full Text] [Related]
27. Single-arm Phase II cancer survival trial designs.
Wu J
J Biopharm Stat; 2016; 26(4):644-56. PubMed ID: 26098141
[TBL] [Abstract][Full Text] [Related]
28. Sequential monitoring of cancer immunotherapy trial with random delayed treatment effect.
Wu J; Zhu L; Li Y
J Biopharm Stat; 2023 Dec; ():1-14. PubMed ID: 38146192
[TBL] [Abstract][Full Text] [Related]
29. Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas.
Abel UR; Jensen K; Karapanagiotou-Schenkel I; Kieser M
J Biopharm Stat; 2015; 25(6):1285-311. PubMed ID: 25629760
[TBL] [Abstract][Full Text] [Related]
30. A free gift: an adaptive strategy in a single-arm trial using an exact test through the binomial distribution.
Wang J
J Biopharm Stat; 2012; 22(6):1127-36. PubMed ID: 23075012
[TBL] [Abstract][Full Text] [Related]
31. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
Tang Y
Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
[TBL] [Abstract][Full Text] [Related]
32. Group sequential design with maximin efficiency robust test for immunotherapy with generalized delayed treatment effect.
Li B; Zhang J; Yang W; Su L; Yan F
Pharm Stat; 2024; 23(1):107-133. PubMed ID: 37859531
[TBL] [Abstract][Full Text] [Related]
33. Adaptive promising zone design for cancer immunotherapy with heterogeneous delayed treatment effect.
Li B; Yan F; Jiang D
J Biopharm Stat; 2024 Apr; ():1-20. PubMed ID: 38615361
[TBL] [Abstract][Full Text] [Related]
34. On sample size determination in multi-armed confirmatory adaptive designs.
Wassmer G
J Biopharm Stat; 2011 Jul; 21(4):802-17. PubMed ID: 21516570
[TBL] [Abstract][Full Text] [Related]
35. Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.
Hamasaki T; Evans SR; Asakura K
J Biopharm Stat; 2018; 28(1):28-51. PubMed ID: 29083951
[TBL] [Abstract][Full Text] [Related]
36. A sample size formula for the supremum log-rank statistic.
Eng KH; Kosorok MR
Biometrics; 2005 Mar; 61(1):86-91. PubMed ID: 15737081
[TBL] [Abstract][Full Text] [Related]
37. Sample size re-estimation for adaptive sequential design in clinical trials.
Gao P; Ware JH; Mehta C
J Biopharm Stat; 2008; 18(6):1184-96. PubMed ID: 18991116
[TBL] [Abstract][Full Text] [Related]
38. Sample size determination for the weighted log-rank test with the Fleming-Harrington class of weights in cancer vaccine studies.
Hasegawa T
Pharm Stat; 2014; 13(2):128-35. PubMed ID: 24497461
[TBL] [Abstract][Full Text] [Related]
39. Sample size calculation for testing differences between cure rates with the optimal log-rank test.
Wu J
J Biopharm Stat; 2017; 27(1):124-134. PubMed ID: 26882262
[TBL] [Abstract][Full Text] [Related]
40. Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects.
Jiménez JL; Stalbovskaya V; Jones B
Pharm Stat; 2019 May; 18(3):287-303. PubMed ID: 30592138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]